Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2011; Volume 201, Supplement 682
The 90th Annual Meeting of The German Physiological Society
3/26/2011-3/29/2011
Regensburg, Germany


THE ROLE OF ADENOSINE AND ATP IN TUBULOGLOMERULAR FEEDBACK AND RBF AUTOREGULATION
Abstract number: P119

*Dautzenberg1 M., Just1 A.

Background: 

Evidence supports involvement of adenosine and ATP in renal blood flow (RBF) autoregulation, but controversy exists regarding the role of ATP in tubuloglomerular feedback (TGF). Since RBF autoregulation is caused by the myogenic response (MR), TGF, and a third, unidentified, regulatory mechanism, we tested the hypothesis that ATP does not mediate TGF, but the third mechanism.

Methods: 

RBF autoregulation and the three regulatory mechanisms were assessed from the response of RBF to rapid experimental changes in renal artery pressure (RAP) in anesthetized rats. The response within the first 6 s after the RAP-rise was interpreted as MR, that between 6 and 25 s as TGF, and 25 to 100 s as third mechanism. A1 adenosine receptors (A1AR) were inhibited by DPCPX (600 mg/kg iv.), and P2X1 ATP receptors (P2X1R) by Suramin (10 mg/kg/min ia.).

Results: 

Suramin abolished P2X1R-responses, but did not affect (p>0.09) total autoregulation (94±6 vs. 96±6% of perfect), MR (34±4 vs. 42±6 regulatory units), TGF (29±4 vs. 35±3 units), or the third mechanism (51±7 vs. 37±2 units). In contrast, DPCPX diminished total autoregulation (72±8 vs. 99±6%, p<0.05) and virtually abolished TGF (9±6 vs. 39±4 units, p<0.001), without affecting (p>0.5) MR (57±7 vs. 60±5 units) or third mechanism (15±4 vs. 21±6 units).

Conclusions: 

P2X1R do not contribute to RBF autoregulation, TGF, or the third autoregulatory mechanism. A1AR, by contrast, support RBF autoregulation by mediating TGF.

To cite this abstract, please use the following information:
Acta Physiologica 2011; Volume 201, Supplement 682 :P119

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE